New updates have been reported about Folia Health.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Folia Health has launched BRAVE-PWS, a fully remote, six‑month observational study that uses its app-based platform to capture home-reported outcomes from caregivers of individuals with Prader-Willi syndrome across the United States. Sponsored by Soleno Therapeutics, the initiative positions Folia’s technology at the center of rare-disease evidence generation by collecting longitudinal data on caregiver well-being, daily routines, and PWS-related symptoms and behaviors.
By running all screening, consent, and data collection through the Folia mobile app, the study demonstrates the company’s ability to execute decentralized research while providing participants with real-time visual feedback on patterns in symptoms and environmental factors. Folia’s CEO and founder, Nell Meosky Luo, emphasized that pragmatic, real-world measurement can inform future research, clinical care strategies, and evaluation of emerging PWS treatments, underscoring the platform’s relevance for biopharma partners and health systems focused on rare and chronic conditions.